|Bid||36.010 x 6700|
|Ask||36.020 x 6000|
|Day's Range||35.910 - 36.190|
|52 Week Range||29.830 - 36.210|
|PE Ratio (TTM)||26.32|
|Dividend & Yield||1.28 (3.61%)|
|1y Target Est||N/A|
Pfizer (PFE: NYSE) By Morgan Stanley ($35.45, Sept. 20) We are upgrading Pfizer stock from Equal-weight to Overweight and raising our price target from $35 to $39. This is a multiple call. Following underperformance, ...
Pfizer's (PFE) key products contributing to growth include Eliquis, Ibrance, Lyrica, Xalkori, Xeljanz, and Xtandi.
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.